Bank employs AI-powered “digital DNA human”
Arab Banking Corporation (Bank ABC), in collaboration with New Zealand tech company, Soul Machines, has announced the launch of “Fatema” – a fully autonomous AI personality that will assist customers online.
Continue reading “Bank employs AI-powered ‘digital DNA human’” »
The most prolific musical artists manage to release one, maybe two, studio albums in a year. Rappers can sometimes put out three or four mixtapes during that same time. However, Auxuman plans to put out a new full-length album, featuring hot up-and-coming artists like Yona, Mony, Gemini, Hexe, and Zoya, every single month. How? The power of artificial intelligence of course.
Before this goes any further, don’t worry: You’re not hopelessly out of touch with today’s pop music. Yona, Mony, Gemini, and the rest of the bunch aren’t real musicians. Well, at least not in the sense that you could meet them and shake their hands. They’re A.I. personalities, each with their own characters and genres, which have been created by Auxuman, an artificial intelligence startup based in London.
Continue reading “A.I. musicians are a growing trend. What does that mean for the music industry?” »
Today, it was announced that the SingularityNET and TODA ecosystems will be joining forces to create scalable platforms and a product accelerator for decentralized AI.
The partnership brings blockchain AI pioneer SingularityNET and its enterprise-AI spinoff Singularity Studio together with TODA.Network and TODAQ from the TODA Protocol family.
Technical teams from both ecosystems are experimenting with bringing the two technologies together on the operational level, by building a “Singularity-on-TODA” system in which SingularityNET AI agents can optionally utilize the TODA protocol rather than Ethereum for their interactions.
In an experiment, DeepMind researchers investigated the extent to which AI agents could generalize learned knowledge to unseen tasks.
Over the next decade, U.S. banks, which are investing $150 billion in technology annually, will use automation to eliminate 200,000 jobs, thus facilitating “the greatest transfer from labor to capital” in the industry’s history. The call is coming from inside the house this time, too—both the projection and the quote come from a recent Wells Fargo report, whose lead author, Mike Mayo, told the Financial Times that he expects the industry to shed 10 percent of all of its jobs.
As reported by the U.S. Air Force Research Laboratory, military scientists have developed a “Terminator-like” liquid metal that can autonomously change the structure, just like in a Hollywood movie.
The scientists developed liquid metal systems for stretchable electronics – that can be bent, folded, crumpled and stretched – are major research areas towards next-generation military devices.
Conductive materials change their properties as they are strained or stretched. Typically, electrical conductivity decreases and resistance increases with stretching.
Trade wars and a global economic slowdown are creating more opportunities for companies looking for better, cheaper automated options.
A first: paralyzed man uses brain signals to control a robot exoskeleton.
Doctors who conducted the trial said though the device was years away from being publicly available, it had the potential to improve patients’ quality of life and autonomy.
The patient, identified only as Thibault, 28, from Lyon, said the technology had given him a new lease of life. Four years ago his life was permanently changed when he fell 40ft (12 metres) from a balcony, severing his spinal cord and leaving him paralysed from the shoulders down.
Continue reading “Paralysed man walks using mind-controlled exoskeleton” »
At the Ending Age-Related Diseases 2019 Conference in New York City, we had the opportunity to interview Dr. Justin Rebo from the drug discovery biotech company BioAge.
BioAge is developing a drug discovery platform that uses machine learning and artificial intelligence to discover targets that have the potential to promote healthy lifespan (healthspan) by slowing down aging and the ill health that it brings.
As the vice president of in-vivo biology at BioAge, Dr. Rebo leads the company’s internal in-vivo platform to find and assess the viability of new druggable targets for aging diseases and biomedical regeneration. With considerable business as well as academic experience in the aging field under his belt, Justin joined the BioAge team in 2018.
